These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 33252854)
1. Predicting the early risk of ophthalmopathy in Graves' disease patients using TCR repertoire. Wang Y; Liu Y; Yang X; Guo H; Lin J; Yang J; He M; Wang J; Liu X; Shi T; Wu L; Zhang C; Ye K; Shi B Clin Transl Med; 2020 Nov; 10(7):e218. PubMed ID: 33252854 [No Abstract] [Full Text] [Related]
2. Parameters predicting outcomes of strabismus surgery in the management of Graves' ophthalmopathy. Nassar MM; Dickinson AJ; Neoh C; Powell C; Buck D; Galal E; Clarke MP J AAPOS; 2009 Jun; 13(3):236-40. PubMed ID: 19395292 [TBL] [Abstract][Full Text] [Related]
3. TSHR intronic polymorphisms (rs179247 and rs12885526) and their role in the susceptibility of the Brazilian population to Graves' disease and Graves' ophthalmopathy. Bufalo NE; Dos Santos RB; Marcello MA; Piai RP; Secolin R; Romaldini JH; Ward LS J Endocrinol Invest; 2015 May; 38(5):555-61. PubMed ID: 25543543 [TBL] [Abstract][Full Text] [Related]
4. Effect of subtotal thyroidectomy on natural history of ophthalmopathy in Graves' disease. Abe Y; Sato H; Noguchi M; Mimura T; Sugino K; Ozaki O; Yoshimura H; Ito K World J Surg; 1998 Jul; 22(7):714-7. PubMed ID: 9606287 [TBL] [Abstract][Full Text] [Related]
5. Postural variation of exophthalmometry in Graves' ophthalmopathy. Asad R; Tewari HK; Ahuja MM; Mithal A Indian J Ophthalmol; 1990; 38(4):166-8. PubMed ID: 2086467 [TBL] [Abstract][Full Text] [Related]
6. Association of Graves' disease and Graves' ophthalmopathy with the polymorphisms in promoter and exon 1 of cytotoxic T lymphocyte associated antigen-4 gene. Zhang Q; Yang YM; Lv XY J Zhejiang Univ Sci B; 2006 Nov; 7(11):887-91. PubMed ID: 17048303 [TBL] [Abstract][Full Text] [Related]
7. Limited genetic susceptibility to severe Graves' ophthalmopathy: no role for CTLA-4 but evidence for an environmental etiology. Villanueva R; Inzerillo AM; Tomer Y; Barbesino G; Meltzer M; Concepcion ES; Greenberg DA; MacLaren N; Sun ZS; Zhang DM; Tucci S; Davies TF Thyroid; 2000 Sep; 10(9):791-8. PubMed ID: 11041456 [TBL] [Abstract][Full Text] [Related]
8. Epidemiology and prevention of Graves' ophthalmopathy. Wiersinga WM; Bartalena L Thyroid; 2002 Oct; 12(10):855-60. PubMed ID: 12487767 [TBL] [Abstract][Full Text] [Related]
9. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Prummel MF; Wiersinga WM; Mourits MP; Koornneef L; Berghout A; van der Gaag R Arch Intern Med; 1990 May; 150(5):1098-101. PubMed ID: 1691908 [TBL] [Abstract][Full Text] [Related]
10. Influence of smoking on Graves' disease with or without ophthalmopathy and nontoxic nodular goiter in Taiwan. Chen YL; Chang TC; Chen CJ J Formos Med Assoc; 1994 Jan; 93(1):40-4. PubMed ID: 7915579 [TBL] [Abstract][Full Text] [Related]
11. Analysis of retroorbital T cell antigen receptor variable region gene usage in patients with Graves' ophthalmopathy. Heufelder AE; Herterich S; Ernst G; Bahn RS; Scriba PC Eur J Endocrinol; 1995 Mar; 132(3):266-77. PubMed ID: 7889172 [TBL] [Abstract][Full Text] [Related]
12. Extraocular muscle antibodies and the occurrence of ophthalmopathy in Graves' disease. de Bellis A; Perrino S; Coronella C; Sansone D; Ruocco G; Tirelli G; Di Martino S; Conte M; Bellastella G; Wall JR; Bellastella A; Bizzarro A Clin Endocrinol (Oxf); 2004 Jun; 60(6):694-8. PubMed ID: 15163332 [TBL] [Abstract][Full Text] [Related]
13. Graves' dermopathy and acropachy are markers of severe Graves' ophthalmopathy. Fatourechi V; Bartley GB; Eghbali-Fatourechi GZ; Powell CC; Ahmed DD; Garrity JA Thyroid; 2003 Dec; 13(12):1141-4. PubMed ID: 14751035 [TBL] [Abstract][Full Text] [Related]
14. Plasma leptin concentrations in patients with Graves' disease with or without ophthalmopathy. Ozata M; Uckaya G; Bolu E; Corapcioglu D; Bingol N; Ozdemir IC Med Sci Monit; 2001; 7(4):696-700. PubMed ID: 11433197 [TBL] [Abstract][Full Text] [Related]
15. Chronology of Graves' ophthalmopathy in an incidence cohort. Bartley GB; Fatourechi V; Kadrmas EF; Jacobsen SJ; Ilstrup DM; Garrity JA; Gorman CA Am J Ophthalmol; 1996 Apr; 121(4):426-34. PubMed ID: 8604736 [TBL] [Abstract][Full Text] [Related]
16. Extraocular muscle repositioning as the last therapeutic option for a patient with a severe course of Graves' Ophthalmopathy: a case report. Rau A; Klopfer M; Rommel N; Rau-Fornefeld M; Kolk A BMC Ophthalmol; 2018 Feb; 18(1):56. PubMed ID: 29482520 [TBL] [Abstract][Full Text] [Related]
17. Serum IL-18 levels are not increased in patients with untreated Graves' ophthalmopathy. Wakelkamp IM; Prummel MF; Wiersinga WM Horm Metab Res; 2004 Jan; 36(1):44-7. PubMed ID: 14983406 [TBL] [Abstract][Full Text] [Related]
18. Immunologically mediated cytotoxicity against human eye muscle cells in Graves' ophthalmopathy. Wang PW; Hiromatsu Y; Laryea E; Wosu L; How J; Wall JR J Clin Endocrinol Metab; 1986 Aug; 63(2):316-22. PubMed ID: 3755139 [TBL] [Abstract][Full Text] [Related]
19. Relationship between Graves' ophthalmopathy and type of treatment of Graves' hyperthyroidism. Marcocci C; Bartalena L; Bogazzi F; Bruno-Bossio G; Pinchera A Thyroid; 1992; 2(2):171-8. PubMed ID: 1525588 [TBL] [Abstract][Full Text] [Related]